Abstract:Antimicrobial drug resistance has emerged as a significant challenge in contemporary medicine due to the proliferation of numerous bacterial strains resistant to all existing antibiotics. Meanwhile, riboswitches have emerged as promising targets for discovering antibacterial drugs. Riboswitches are regulatory elements in certain bacterial mRNAs that can bind to specific molecules and control gene expression via transcriptional termination, prevention of translation, or mRNA destabilization. By targeting riboswitches, we aim to develop innovative strategies to combat antibiotic-resistant bacteria and enhance the efficacy of antibacterial treatments. This convergence of challenges and opportunities underscores the ongoing quest to revolutionize medical approaches against evolving bacterial threats. For the first time, this innovative review describes the rational design and applications of chimeric antisense oligonucleotides as antibacterial agents targeting four riboswitches selected based on genome-wide bioinformatic analyses. The antisense oligonucleotides are coupled with the cell-penetrating oligopeptide pVEC, which penetrates Gram-positive and Gram-negative bacteria and specifically targets glmS, FMN, TPP, and SAM-I riboswitches in Staphylococcus aureus, Listeria monocytogenes, and Escherichia coli. The average antibiotic dosage of antisense oligonucleotides that inhibits 80% of bacterial growth is around 700 nM (4.5 μg/mL). Antisense oligonucleotides do not exhibit toxicity in human cell lines at this concentration. The results demonstrate that these riboswitches are suitable targets for antibacterial drug development using antisense oligonucleotide technology. The approach is fully rational because selecting suitable riboswitch targets and designing ASOs that target them are based on predefined criteria. The approach can be used to develop narrow or broad-spectrum antibiotics against multidrug-resistant bacterial strains for a short time. The approach is easily adaptive to new resistance using targeting NGS technology.

Inhibition of Bacterial RNA Polymerase Function and Protein-Protein Interactions: A Promising Approach for Next-Generation Antibacterial Therapeutics

[New Inhibitors Targeting Bacterial RNA Polymerase].

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles

Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction

Discovery of Inhibitors Targeting Protein-Protein Interaction between Bacterial RNA Polymerase and NusG as Novel Antimicrobials

RNA-based Therapeutics: an Overview and Prospectus

Mechanism of inhibition of bacterial RNA helicases by diazo dyes and implications for antimicrobial drug development

Research Advances of Aminoacyl-tRNA Synthetase Inhibitors As Novel Anti-infective Agents

RNA as a drug target.

Opportunities for Riboswitch Inhibition by Targeting Co-Transcriptional RNA Folding Events

Paradigm shift in discovering next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and biofilm formation in bacteria with small molecules.

First-In-Class Inhibitor of Ribosomal RNA Synthesis with Antimicrobial Activity against Staphylococcus aureus

Antisense Oligonucleotides: the glint of new antimicrobial agent

RNAi technology: A Novel approaches against fungal infections

Novel Aptamer Strategies in Combating Bacterial Infections: From Diagnostics to Therapeutics

Aminoacyl-tRNA synthetase inhibitors as potent antibacterials.

Inhibition of RNA-binding proteins with small molecules

Aminoglycoside Mimetics As Small-Molecule Drugs Targeting RNA

Targeting FMN, TPP, SAM-I, and glmS Riboswitches with Chimeric Antisense Oligonucleotides for Completely Rational Antibacterial Drug Development

Structural Basis for Full-Spectrum Inhibition of Translational Functions on a Trna Synthetase